BioPharmX Corporation (BPMX) belonging to the Healthcare sector has surged 16.06% and closed its last trading session at $0.23.
The company reported its EPS on 4/29/2018. Currently, the stock has a 1 Year Price Target of $1.05.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
BioPharmX Corporation on 4/29/2018 reported its EPS as $-0.05 with the analysts projecting the EPS of the stock as $-0.06. The company beat the analyst EPS Estimate with the difference of $0.01. This shows a surprise factor of 0.167%.
Many analysts have provided their estimated foresights on BioPharmX Corporation Earnings, with 2 analysts believing the company would generate an Average Estimate of $-0.02.
Whereas they predicted High and Low Earnings Estimate as $-0.02 and $-0.02 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.05.
Analysts are also projecting an Average Revenue Estimate for BioPharmX Corporation as $10000 in the Current Quarter. This estimate is provided by 2 analysts.
BioPharmX Corporation (BPMX) has the market capitalization of $46.07 Million. The company rocked its 52-Week High of $0.479 and touched its 52-Week Low of $0.1.
The stock has Return on Assets (ROA) of -230 percent. Return on Equity (ROE) stands at -620.6% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 110.53 Percent. The company has Beta Value of -0.47 and ATR value of 0.02. The Weekly and Monthly Volatility stands at 8.79% and 6.97%.